Immediate Impact
1 from Science/Nature 51 standout
Citing Papers
Cancer cell metabolism and antitumour immunity
2024 Standout
CAR immune cells: design principles, resistance and the next generation
2023 StandoutNature
Works of U. Ohnmacht being referenced
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
2018
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| U. Ohnmacht | 262 | 261 | 130 | 20 | 529 | |
| J.M. Trent | 281 | 167 | 76 | 20 | 559 | |
| Sophie Barrett | 250 | 289 | 54 | 17 | 648 | |
| Peter L. Depowski | 311 | 296 | 86 | 15 | 526 | |
| Gholamreza Safaee Ardekani | 296 | 210 | 80 | 18 | 540 | |
| Prakash Peddi | 196 | 276 | 125 | 33 | 549 | |
| Timo Pietiläinen | 228 | 262 | 71 | 16 | 530 | |
| Dominique Agbor‐Tarh | 143 | 349 | 90 | 22 | 494 | |
| Magnus Zethoven | 205 | 187 | 108 | 20 | 477 | |
| Marialaura Petroni | 416 | 194 | 53 | 25 | 607 | |
| Marianne Großer | 203 | 105 | 129 | 19 | 499 |
All Works
Loading papers...